BR112021019170A2 - Combinações úteis em um método para tratar sarcoma - Google Patents
Combinações úteis em um método para tratar sarcomaInfo
- Publication number
- BR112021019170A2 BR112021019170A2 BR112021019170A BR112021019170A BR112021019170A2 BR 112021019170 A2 BR112021019170 A2 BR 112021019170A2 BR 112021019170 A BR112021019170 A BR 112021019170A BR 112021019170 A BR112021019170 A BR 112021019170A BR 112021019170 A2 BR112021019170 A2 BR 112021019170A2
- Authority
- BR
- Brazil
- Prior art keywords
- subject
- useful combinations
- sarcoma
- treat sarcoma
- treating sarcoma
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962825017P | 2019-03-27 | 2019-03-27 | |
| PCT/US2020/025532 WO2020198705A1 (en) | 2019-03-27 | 2020-03-27 | Combinations useful in a method for treating sarcoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021019170A2 true BR112021019170A2 (pt) | 2022-03-03 |
Family
ID=72609016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021019170A BR112021019170A2 (pt) | 2019-03-27 | 2020-03-27 | Combinações úteis em um método para tratar sarcoma |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220152024A1 (https=) |
| EP (1) | EP3947379A4 (https=) |
| JP (1) | JP7602481B2 (https=) |
| CN (1) | CN114096537B (https=) |
| AU (1) | AU2020248103A1 (https=) |
| BR (1) | BR112021019170A2 (https=) |
| CA (1) | CA3134648A1 (https=) |
| EA (1) | EA202192349A1 (https=) |
| IL (1) | IL286647A (https=) |
| MX (1) | MX2021011688A (https=) |
| WO (1) | WO2020198705A1 (https=) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH593266A5 (https=) * | 1973-09-20 | 1977-11-30 | Delalande Sa | |
| AU2002228922A1 (en) * | 2000-12-12 | 2002-06-24 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| AU2007335744A1 (en) * | 2006-12-20 | 2008-06-26 | Alberto A. Gabizon | Method for administration of pegylated liposomal doxorubicin |
| KR20220143164A (ko) * | 2012-11-21 | 2022-10-24 | 피티씨 테라퓨틱스, 인크. | 치환된 리버스 피리미딘 ｂｍｉ-1 저해제 |
| CN113164479A (zh) * | 2018-08-17 | 2021-07-23 | Ptc医疗公司 | 用于治疗胰腺癌的方法 |
| SG11202109503TA (en) * | 2019-03-11 | 2021-09-29 | Ptc Therapeutics Inc | Compound form having enhanced bioavailability and formulations thereof |
-
2020
- 2020-03-27 MX MX2021011688A patent/MX2021011688A/es unknown
- 2020-03-27 CA CA3134648A patent/CA3134648A1/en active Pending
- 2020-03-27 EP EP20776386.3A patent/EP3947379A4/en not_active Withdrawn
- 2020-03-27 CN CN202080039624.8A patent/CN114096537B/zh active Active
- 2020-03-27 WO PCT/US2020/025532 patent/WO2020198705A1/en not_active Ceased
- 2020-03-27 AU AU2020248103A patent/AU2020248103A1/en not_active Abandoned
- 2020-03-27 JP JP2021557396A patent/JP7602481B2/ja active Active
- 2020-03-27 US US17/441,355 patent/US20220152024A1/en not_active Abandoned
- 2020-03-27 BR BR112021019170A patent/BR112021019170A2/pt not_active Application Discontinuation
- 2020-03-27 EA EA202192349A patent/EA202192349A1/ru unknown
-
2021
- 2021-09-23 IL IL286647A patent/IL286647A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3947379A1 (en) | 2022-02-09 |
| JP7602481B2 (ja) | 2024-12-18 |
| CN114096537B (zh) | 2025-01-10 |
| EA202192349A1 (ru) | 2022-02-01 |
| CA3134648A1 (en) | 2020-10-01 |
| US20220152024A1 (en) | 2022-05-19 |
| CN114096537A (zh) | 2022-02-25 |
| WO2020198705A1 (en) | 2020-10-01 |
| AU2020248103A1 (en) | 2021-10-21 |
| IL286647A (en) | 2021-10-31 |
| JP2022519930A (ja) | 2022-03-25 |
| EP3947379A4 (en) | 2022-12-21 |
| MX2021011688A (es) | 2022-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018004620A2 (pt) | moduladores da expressão de kras | |
| CL2021003134A1 (es) | Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos | |
| BR112017028194A2 (pt) | moduladores de diaciglicerol aciltransferase 2 (dgat2) | |
| BR112018012914A2 (pt) | composto, método para tratar, prevenir ou melhorar um ou mais sintomas de câncer, método para tratar, prevenir ou melhorar um ou mais sintomas de uma doença inflamatória e composição farmacêutica | |
| AR111986A1 (es) | Suplemento y composición de pienso animal | |
| CR20240267A (es) | Moduladores de la expresión de pnpla3 (divisional exp. 2021-0180) | |
| CR20190471A (es) | Moduladores de la expresión de pcsk9 | |
| NI202000085A (es) | Moduladores de la expresión de apol1 | |
| BR112019005040A2 (pt) | aplicação de pridopidina para tratamento de síndrome de rett | |
| ECSP20081995A (es) | Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias | |
| CO2020008769A2 (es) | Moduladores de la expresión dnm2 | |
| MX2021010152A (es) | Moduladores de la expresion de malat1. | |
| CL2021000585A1 (es) | Métodos para tratar la pancreatitis | |
| MX2017010654A (es) | Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres. | |
| BR112017014914A2 (pt) | terapia combinada para hipertensão pulmonar | |
| BR112018069115A2 (pt) | composições, composições de revestimento aquosas e métodos para melhorar a estabilidade de congelamento/descongelamento de composições de revestimento aquosas | |
| CO2021007006A2 (es) | Moduladores de la expresión de irf5 | |
| BR112019004906A2 (pt) | combinação incluindo abx196 para o tratamento de câncer | |
| CL2021003442A1 (es) | Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer. | |
| BR112021019170A2 (pt) | Combinações úteis em um método para tratar sarcoma | |
| MX2020003554A (es) | Moduladores de la expresion de enac. | |
| BR112017028381A2 (pt) | agente para melhora da hiperatividade do músculo detrusor com contratilidade prejudicada | |
| MX2021003496A (es) | Potenciacion del tratamiento contra helmintos. | |
| CO2021000349A2 (es) | Moléculas de anticuerpo de componente de complemento 5 y sus usos | |
| AR117079A1 (es) | Moduladores de la expresión de foxp3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 471/04 , C07D 403/04 , C07D 487/04 Ipc: C07D 471/04 (2006.01), C07D 403/04 (2006.01), C07D |
|
| B25G | Requested change of headquarter approved |
Owner name: PTC THERAPEUTICS, INC. (US) |
|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |